Thymos Health
Your Autoimmune Hepatitis Journey

Still on steroids.
Still relapsing every time you taper off.
Still watching your liver labs.

You're not alone. This is how autoimmune hepatitis (AIH) is typically managed — and an honest look at what that journey costs, and what it leads to, over time.

31.2 out of 100,000 Americans suffer with autoimmune hepatitis – with incidence rate rising annually.1
80% of patients achieve remission with prednisone ± azathioprine.2
Up to 80% of patients relapse after treatment is stopped.3
10–20% eventually require a liver transplant.4

How autoimmune hepatitis is typically treated

Autoimmune hepatitis is one of the few autoimmune diseases where the first-line therapy actually works for most patients — the problem is what happens when you try to stop it.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your hepatologist starts you on High-Dose Prednisone
Prednisone/prednisolone 40–60mg/day, tapered as liver enzymes normalize
What your doctor says
"Your liver enzymes and IgG are quite elevated. We need to start high-dose steroids right away to bring the inflammation under control before it causes more liver damage."
At least 80% of patients achieve remission2
High doses (40–60mg) needed initially, with real steroid side effects
Response assessed within 7–14 days
Annual cost before insurance (generic) ~$100–$400
Providers seen before this was prescribed
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Azathioprine added as a steroid-sparing agent once response begins
Step 2: Once you respond, you add Azathioprine
1–2mg/kg/day — added to allow prednisone tapering while maintaining remission
What your doctor says
"Now that your labs have improved, we'll add azathioprine so we can start reducing your steroid dose. Long-term steroid use has real risks we want to avoid."
83% remained in remission on azathioprine alone (median 67 mo)5
~15% discontinue azathioprine in year one, mainly for intolerance6
Maintenance typically required for 2–3+ years minimum
Annual cost before insurance (generic) ~$150–$600
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Incomplete response or intolerance — second-line agent considered
Step 3: For non-responders or intolerance, you try Mycophenolate or Tacrolimus
Second-line agents for the 13–20% of patients with an incomplete response to standard therapy.7
What your doctor says
"Since you're not achieving full remission — or not tolerating azathioprine — we'll switch to a second-line immunosuppressant. This is where treatment gets more individualized."
Requires ongoing drug-level and liver-function monitoring
Annual cost before insurance ~$1,500–$5,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
When “in remission” meets “off medication” Relapse, Cirrhosis & Transplant Evaluation
The central paradox of autoimmune hepatitis: therapy usually works, but stopping it usually doesn't hold
What Your Doctor says
"Your labs looked great for two years, so we tried tapering you off. Unfortunately your enzymes have flared again — we'll need to restart treatment and likely keep you on it indefinitely."
10–20% eventually require liver transplantation4
80%
Relapse rate after stopping treatment, even after confirmed remission3
83%
Maintain remission if kept on azathioprine long-term5
36–68%
Autoimmune hepatitis recurrence rate in the new liver within 5 years post-transplant8
The withdrawal dilemma, by the numbers
Achieve remission on prednisone ± azathioprine ~80%
Incomplete responders even after 3 years 13–20%
Relapse rate after stopping treatment Up to 80%
Maintain remission on azathioprine monotherapy long-term 83% (median 67 mo)
What long-term management actually looks like
🔁 Most patients never truly “stop” treatment. Because periodic liver biopsy findings don't reliably predict who will relapse, and because relapse rates after withdrawal run as high as 80%, most patients end up on some form of indefinite immunosuppression rather than a defined treatment course.9
💊 The steroid-sparing strategy exists precisely because long-term steroids are so costly to the body. The entire rationale for adding azathioprine is to allow prednisone tapering — an implicit acknowledgment that years of high-dose steroids carry real cumulative harm (bone loss, diabetes, cataracts, weight gain).
🫀 Transplant is not a rare outcome — it's a real minority endpoint. Between 10% and 20% of autoimmune hepatitis patients eventually require liver transplantation, most often after progression to decompensated cirrhosis despite treatment.4
🔄 Transplantation doesn't end the disease. autoimmune hepatitis recurs in the new liver in 36–68% of transplant recipients within 5 years — meaning even the most aggressive intervention available doesn't guarantee a cure.8
⚠ Remission and cure are not the same thing
Autoimmune hepatitis treatment is genuinely effective at inducing remission for most patients — that's real, documented success. But “in remission” in autoimmune hepatitis almost always means “on ongoing immunosuppression,” and the disease is quick to return the moment that support is removed.

What autoimmune hepatitis is really costing you

Generic steroids and azathioprine are inexpensive — but years of monitoring labs, managing steroid side effects, and the risk of a relapse or transplant workup add real cost that a simple prescription total doesn't capture.

Based on your journey above–adjust the numbers to match your situation.
Work days affected by flares or steroid side effects in the last 12 months
Your hourly wage (for lost income calculation)
Your estimated total annual cost of autoimmune hepatitis $0
Drug out-of-pocket costs $0
Lost income (missed days) $0
Reduced productivity at work (presenteeism) $0
Fatigue, steroid side effects, and the anxiety of monitoring for relapse all reduce day-to-day output even between flares
If your care reaches the last phase of this journey — Mycophenolate or Tacrolimus
$0
Projected patient out-of-pocket cost for a full year at this phase, given your coinsurance selection for it above (or a typical default if you haven't reached it yet)

What your insurer is paying

Autoimmune hepatitis drugs themselves are inexpensive generics — but the disease's high relapse rate means your plan often ends up paying for the same induction therapy more than once, plus the cost of a transplant workup in a meaningful minority of patients.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your autoimmune hepatitis each year
Based on your treatment journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your autoimmune hepatitis care $0
Immunosuppressant drug spend (payer portion)
~80% of net price after patient coinsurance; prednisone and azathioprine are both inexpensive generics
$0
Medical costs (hepatology visits, labs, imaging, biopsy)
Frequent liver panels and periodic biopsy to confirm histologic remission before any withdrawal attempt
~$3,200
Have you relapsed after a treatment taper, or progressed toward cirrhosis?
Liver transplant evaluation and listing is one of the largest single cost events in autoimmune gastroenterology
Because up to 80% of patients relapse after stopping treatment, payers frequently fund repeated rounds of induction-dose therapy rather than a single completed course.
Payer cost projection if care reaches the last phase of this journey — Mycophenolate or Tacrolimus
$0
Estimated annual payer spend at that phase: ~80% of drug price plus baseline medical costs, excluding any flare/crisis event above
⚑ Why autoimmune hepatitis is cheap on paper but expensive in practice
The drugs themselves are some of the least expensive on this site. The real cost driver is the disease's biology: high relapse rates after withdrawal mean many patients cycle back to induction-dose steroids repeatedly, and 10–20% eventually reach transplant — an outcome that dwarfs years of prior drug spend combined.
Understanding Your Risk

What the research shows over time

These outcomes are not inevitable — but they are the documented range of what happens across the autoimmune hepatitis treatment and withdrawal cycle.

Based on peer-reviewed clinical data
Long-term outcomes for autoimmune hepatitis patients on today's standard of care
💊
~80% of patients achieve biochemical remission with prednisone alone or combined with azathioprine — genuinely effective first-line therapy2
🔁
Up to 80% relapse after treatment is stopped, even following confirmed remission — the central challenge of autoimmune hepatitis management3
🫀
10–20% of patients eventually require liver transplantation, most often after progression to decompensated cirrhosis4
🔄
36–68% of transplant recipients experience autoimmune hepatitis recurrence in the new liver within 5 years8
✦ A different journey exists

Thymos Health offers another way

Conventional autoimmune hepatitis care treats remission and cure as the same thing, often leading to repeated relapse-and-restart cycles. Thymos goes further – synthesizing your liver labs, biopsy history, and treatment response to identify who might safely taper, and building steroid-sparing strategies around your specific relapse risk.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next follow-up in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] Epidemiology of Autoimmune Hepatitis (AIH) in the United States Between 2014 and 2019: A Population-based National Study. PubMed, 2020 (n=37,161,280 screened; 11,600 autoimmune hepatitis cases). Estimated U.S. AIH prevalence: 31.2 per 100,000; a separate Kaiser Permanente Northern California cohort found prevalence roughly doubling from 9.1 (2010) to 18.8 (2019) per 100,000.
PMID: 33074948
[2] The medical treatment for autoimmune hepatitis through corticosteroid to new immunosuppressive agents: A concise review. ScienceDirect, 2019. At least 80% of patients with autoimmune hepatitis can be placed into remission with prednisone monotherapy or in combination with azathioprine.
Source: sciencedirect.com
[3] Methods and compositions for treatment/diagnosis of autoimmune hepatitis (patent filings summarizing clinical literature), 2019–2021. Up to 80% of patients experience relapse after treatment withdrawal, even following confirmed biochemical and histologic remission, requiring immunosuppressive therapy to be restarted.
Source: USPTO filing
[4] Global epidemiology and determinants of autoimmune hepatitis recurrence post-liver transplantation: A systematic review and meta-analysis. ScienceDirect, 2025. Approximately 10–20% of patients with autoimmune hepatitis will ultimately require liver transplantation during the course of their disease.
Source: sciencedirect.com
[5] Azathioprine for Long-Term Maintenance of Remission in Autoimmune Hepatitis. New England Journal of Medicine, 1995 (n=72, median follow-up 67 months). 83% of patients remained in remission on azathioprine monotherapy (2mg/kg/day) after prednisolone withdrawal; 45 of 48 follow-up biopsies showed inactive or minimal disease.
Source: nejm.org
[6] High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. PMC, multicenter international retrospective cohort. Azathioprine discontinuation rate ~15% within the first year of treatment, primarily due to intolerance (nausea, vomiting); early vs. delayed initiation did not affect remission or discontinuation rates.
PMC: PMC7496382
[7] Autoimmune Hepatitis (AIH) Treatment & Management. Medscape, clinical reference. Incomplete response — improvement insufficient to satisfy remission criteria — occurs in an estimated 13% of patients; many require indefinite low-dose immunosuppression to prevent clinical deterioration.
Source: emedicine.medscape.com
[8] Autoimmune hepatitis and liver transplantation: Indications, and recurrent and de novo autoimmune hepatitis. PMC, 2022. Autoimmune hepatitis recurs in the transplanted liver in 36%–68% of recipients within 5 years post-transplant.
PMC: PMC8968478
[9] The medical treatment for autoimmune hepatitis through corticosteroid to new immunosuppressive agents: A concise review. ScienceDirect, 2019. Periodic abnormal findings on liver biopsy do not reliably predict relapse; continued interface hepatitis with otherwise normal biochemistry carries a very high recurrence rate if medications are stopped.
Source: sciencedirect.com